For years, Squid Compression has helped ease the pain of patients in doctor's offices. Now, anyone can get the treatment on the go. Photo via squidgo.com

Houston company creates portable device that eases pain without the use of drugs

No pain, just gain

Many of the estimated 50 million Americans who suffer from chronic pain turn to drugs — including heavily abused opioids — to relieve their symptoms. Houston-based startup Portable Therapeutix LLC's drug-free solution to pain management seeks to put a dent in the market for prescription painkillers.

In 2018, Houston-based Portable Therapeutix introduced Squid Go, a portable device that's designed to ease the pain and swelling of sore joints and muscles. It's a follow-up to the company's Squid Compression, a pain management device launched in 2013 for patients at rehabilitation centers, hospitals, doctor's offices, and the like.

Squid Go enables consumers to apply two approaches — cold therapy and compression therapy — to relieving joint pain and swelling caused by arthritis, bouncing back from athletic activities, or recovering from an injury or surgery involving muscles and joints. Variations of the device can treat ankle, back, leg, knee, shoulder, or wrist pain.

To reap the benefits of Squid Go, a consumer uses the device for just 15 minutes. Squid Go — which combines a cold gel pack with proprietary compression technology — features special air pockets that inflate and deflate, gently massaging the body part needing treatment. That massaging boosts circulation and reduces swelling.

"Increased circulation brings more nutrient- and oxygen-rich blood to the area, promoting recovery," says Sam Stolbun, co-founder of Portable Therapeutix. "Meanwhile, [the] gentle compression also drives the pain-relieving cold from the gel pack deeper into the tissues to alleviate soreness and discomfort."

The coldness of the gel pack fights inflammation.

Stolbun says someone can take the lightweight, portable Squid Go device to the office, to the gym or anywhere else for on-the-go pain relief. It even can be used without the cold gel pack for compression-only therapy to improve circulation and decrease swelling. The Squid Go pump delivers about 15 treatments before it needs to be recharged.

Squid Compression received clearance from the U.S. Food and Drug Administration as a prescription-only device in 2013 and gained over-the-counter status in 2014. The consumer version, Squid Go, employs the same technology and operates the same way as Squid Compression, so a second FDA stamp of approval wasn't required.

Pricing for the heavy-duty Squid Compression system starts at $700. The consumer-friendly Squid Go system goes for $300 or $350, depending on its purpose. Users can buy extra wraps and gel packs to supplement the system.

Stolbun says he and co-founder Shai Schubert developed the Squid devices after realizing that existing pain-fighting cold packs provided only superficial relief, while water-based treatments were inconvenient and offered no compression advantages. Still other cold and compression therapies on the market are expensive and generally aren't covered by health insurance, he says.

Stolbun says that "it became apparent that a reasonably priced, well-made, portable, and effective pain relief and recovery device would meet a need for a broad range of consumers — from athletes to seniors."

Stolbun, a sports enthusiast and bakery mogul, and Schubert, a scientist and entrepreneur, established Portable Therapeutix in 2011.

The company's debut product, Squid Compression, still enjoys success, but Stolbun says the company has shifted its focus to Squid Go. Portable Therapeutix plans to pump up sales for Squid Go via its online presence, he says, as well as through physical therapists, sports trainers and other professionals who've used Squid Compression but want to offer the less pricey Squid Go model to their clients for in-home treatment.

Portable Therapeutix is backed by private investors; the amount of funding it has received isn't available. The company doesn't release revenue and profit figures.

Today, the company employs just one person in Houston but will add workers as its distribution pipeline expands, Stolbun says. Sales, marketing, and customer service representatives are scattered around the country. Stolbun, the CEO, is based in Houston, while Schubert, the chief technical officer, is based in Boston.

Portable Therapeutix relies, in part, on word-of-mouth praise to promote Squid Go. Among those hailing the device is Lee Ward of Houston, who describes himself as a competitive tennis player.

On the Squid Go website, Ward explains that he'd been suffering from progressively worsening tendonitis in his knees for a couple of years.

"I tried a number of remedies, including ice and gel packs, immediately following my tennis workout, but both remedies were ineffective and difficult to use," Ward says in his online testimonial.

He then discovered Squid Go and became a fan.

"The best thing about [Squid Go] is its ease of use. It provides a quick, effective treatment that makes it ideal for daily use by both the serious and recreational athlete," Ward says.

Smart tech

Courtesy of Squid Go

Squid Go combines a cold gel pack with proprietary compression technology and features special air pockets that inflate and deflate, gently massaging the body part needing treatment.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Austin company to bring AI-powered school to The Woodlands

AI education

Austin-based Alpha School, which operates AI-powered private schools, is opening its first Houston-area location in The Woodlands.

The 8,000-square-foot school, scheduled to be ready for the 2026-27 academic year, initially will serve students in kindergarten through eighth grade. Alpha says the school will offer “open workshop spaces and innovative classrooms that support personalized instruction, core academics, leadership development, and real-world life skills.”

Alpha sets aside two hours each school day for the AI-driven, self-paced study of core subjects like math, reading and science. The rest of each school day consists of life-skills workshops focusing on topics such as leadership and financial literacy.

Alpha’s school in The Woodlands has begun accepting applications for the 2026-27 school year. Annual tuition costs $40,000.

“The Woodlands is one of the most dynamic, forward-thinking communities in Texas, and Alpha is proud to bring

an innovative educational model that complements its strong academic foundation,” says Rachel Goodlad, head

of expansion for Alpha.

Founded in 2014, Alpha School combines adaptive technology-driven instruction with immersive life-skills workshops. Its model emphasizes mastery-based learning in core subjects alongside development of communication, critical thinking, financial literacy and leadership skills. It operates more than 15 schools across the country.

Elsewhere in Texas, Alpha operates schools in Austin, Brownsville, Fort Worth and Plano. Alpha also operates 12 Texas Sports Academy campuses in Texas, including locations in Houston, Pearland and Richmond, along with a NextGen Academy esports school in Austin, a school for gifted students in Georgetown, and lower-cost Nova Academy campuses in Austin and Bastrop.

Alpha has fans and critics. While supporters tout students’ high achievement rates, detractors complain about the high tuition and the AI-influenced depersonalization of education.

“Students and our country need to be in relationship with other human beings,” Randi Weingarten, president of the American Federation of Teachers, a teachers union, tells The New York Times. “When you have a school that is strictly AI, it is violating that core precept of the human endeavor and of education.”

Alpha co-founder MacKenzie Price, a podcaster and social media influencer, doesn’t share Weingarten’s views.

“Parents and teachers: We need to embrace this change,” Price wrote after President Trump signed an executive order promoting AI in schools.

The Times notes that Alpha doesn’t employ AI as a tutor or a supplement. Rather, the newspaper says, AI is “the school’s primary educational driver to move students through academic content.”

Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”